Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S. Tura, P. Mazza, F. Gherlinzoni, P. L. Zinzani, G. Poletti, G. Visani, R. M. Lemoli, M. Cavo, P. Galieni, C. Tassi, R. Zanchini

Research output: Contribution to journalArticle

Abstract

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

Original languageEnglish
Pages (from-to)123-125
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 1989

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Tura, S., Mazza, P., Gherlinzoni, F., Zinzani, P. L., Poletti, G., Visani, G., Lemoli, R. M., Cavo, M., Galieni, P., Tassi, C., & Zanchini, R. (1989). Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemotherapy and Pharmacology, 23(2), 123-125. https://doi.org/10.1007/BF00273532